chemistry news, science news, chemicals, molecules
  • Sciencebase.com on Facebook
  • Blogroll

The US Food and Drug Administration (FDA) has approved Tysabri (Natalizumab), a monoclonal antibody for the treatment of moderate to severe Crohn’s disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn’s disease therapies. So reports MediceNews.net.

More on this story about the Crohn’s disease drug approval here.

Comments are closed.